PPARGC1A and Other metabolic disease: In obesity‐induced MA, SFN prevents obesity‐related metabolic disorders by targeting the HDAC8‐PGC1α axis, thereby enhancing mitochondrial biogenesis and function (Yang et al. 2023), and it improves glucose and lipid metabolic dysregulation caused by a high‐fat diet (Luo et al. 2024).